Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Adamas Pharmaceuticals Inc. (ADMS)

4.28   0.16 (3.88%) 10-01 16:03
Open: 4.14 Pre. Close: 4.12
High: 4.38 Low: 4.05
Volume: 198,626 Market Cap: 121M
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. The company is headquartered in Emeryville, California and currently employs 134 full-time employees. The firm is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. The company offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. The company has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). The company has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.262 - 4.286 4.286 - 4.305
Low: 4.018 - 4.051 4.051 - 4.078
Close: 4.071 - 4.12 4.12 - 4.16

Technical analysis

as of: 2020-10-01 3:30:06 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 5.81     One year: 6.48
Support: Support1: 4.04    Support2: 3.36
Resistance: Resistance1: 4.97    Resistance2: 5.55
Pivot: 4.41
Moving Average: MA(5): 4.17     MA(20): 4.62
MA(100): 3.49     MA(250): 4.02
MACD: MACD(12,26): -0.07     Signal(9): 0.02
Stochastic oscillator: %K(14,3): 13.01     %D(3): 6.72
RSI: RSI(14): 46.97
52-week: High: 7.45  Low: 1.90  Change(%): -2.5
Average Vol(K): 3-Month: 52980  10-Days: 29217

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
ADMS has closed above bottom band by 42.7%. Bollinger Bands are 15.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 01 Oct 2020
Adamas appoints new Chief Medical Officer, Adrian Quartel, MD - GlobeNewswire

Wed, 23 Sep 2020
Is Adamas Pharmaceuticals Inc (ADMS) Stock Near the Top of the Drug Manufacturers - Specialty & Generic Industry? - InvestorsObserver

Fri, 11 Sep 2020
Adamas Pharmaceuticals Inc. (ADMS) Plunges 15.02% on September 11 - Equities.com

Fri, 11 Sep 2020
Adamas Announces New Employment Inducement Grant - Yahoo Finance

Fri, 11 Sep 2020
Adamas presents new post-hoc data analysis for GOCOVRI® in Parkinson's disease patients with dyskinesia at the 2020 Movement Disorder Society Virtual Congress - GlobeNewswire

Tue, 08 Sep 2020
Adamas to Present at Upcoming HC Wainwright Conference - Yahoo Finance

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Underperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Outperform Debt to Equity: Underperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers General Specialty & Generic
Shares Out. (M) 28
Shares Float (M) 19
% Held by Insiders 2.81
% Held by Institutions 79.07
Shares Short (K) 855
Shares Short P. Month (K) 783

Stock Financials

EPS -2.784
EPS Est This Year -3.770
EPS Est Next Year -3.420
Book Value (p.s.) -0.860
Profit Margin -122.52
Operating Margin -98.02
Return on Assets (ttm) -23.4
Return on Equity (ttm) -851.3
Qtrly Rev. Growth 48.1
Gross Profit (p.s.) 1.845
Sales Per Share 2.248
EBITDA (p.s.) -2.168
Qtrly Earnings Growth
Operating Cash Flow (M) -67
Levered Free Cash Flow (M) -44

Stock Valuations

PE Ratio -1.56
PEG Ratio
Price to Book value -5.05
Price to Sales 1.93
Price to Cash Flow -1.85

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.